Akari Therapeutics Files 8-K: Material Agreement & Equity Update
Ticker: AKTX · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1541157
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
Related Tickers: AKTX
TL;DR
AKTX signed a material deal, sold equity, and filed financials on Oct 14th.
AI Summary
Akari Therapeutics Plc entered into a material definitive agreement on October 14, 2025. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Akari Therapeutics Plc is incorporated in England and Wales and its stock is traded under the ticker AKTX.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial position and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks related to terms, valuation, and regulatory compliance.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- October 14, 2025 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation
- 001-36288 (identifier) — SEC File Number
- 98-1034922 (identifier) — EIN
- AKTX (ticker) — Trading Symbol
FAQ
What is the nature of the material definitive agreement entered into by Akari Therapeutics Plc?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 14, 2025.
What type of equity securities were sold in the unregistered sales?
The filing mentions unregistered sales of equity securities but does not provide specific details on the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on October 14, 2025.
Where is Akari Therapeutics Plc incorporated?
Akari Therapeutics Plc is incorporated in England and Wales.
What are the previous names of Akari Therapeutics Plc?
The company was formerly known as Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
Filing Stats: 2,036 words · 8 min read · ~7 pages · Grade level 13.6 · Accepted 2025-10-16 09:20:26
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $0.80 — anying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the
- $2.5 m — fering are expected to be approximately $2.5 million, excluding any proceeds from any
- $0.98 — es E Warrants have an exercise price of $0.98 per share, subject to customary adjustm
- $75,000 — -accountable expense allowance of up to $75,000. The Placement Agent or its designees w
- $1.00 — o 125,000 ADSs, at an exercise price of $1.00 per share and will have a 5-year term f
Filing Documents
- form8-k.htm (8-K) — 60KB
- ex5-1.htm (EX-5.1) — 130KB
- ex10-1.htm (EX-10.1) — 282KB
- ex10-2.htm (EX-10.2) — 101KB
- ex10-3.htm (EX-10.3) — 111KB
- ex10-4.htm (EX-10.4) — 111KB
- ex10-5.htm (EX-10.5) — 113KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-25-018269.txt ( ) — 1305KB
- aktx-20251014.xsd (EX-101.SCH) — 4KB
- aktx-20251014_def.xml (EX-101.DEF) — 26KB
- aktx-20251014_lab.xml (EX-101.LAB) — 36KB
- aktx-20251014_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: October 16, 2025 By: /s/ Torsten Hombeck Name: Torsten Hombeck Title: Chief Financial Officer